Key Highlights
- Loss per share was USD 0.72, matching an estimate of a USD 0.72 loss.
- Net loss was USD 6.20 million, compared with USD 3.44 million.
- Research and development expenses were USD 4.44 million, against USD 2.59 million.
- Cash and investments were reported as USD 52.63 million and USD 76.81 million.
Monopar Therapeutics (NASDAQ:MNPR) reported a third quarter 2026 loss per share of USD 0.72, matching an estimate of a USD 0.72 loss, compared with a loss of USD 0.48 in the third quarter of 2025. The net loss was USD 6.20 million, compared with USD 3.44 million.
The loss from operations was USD 7.47 million, compared with USD 4.09 million, and interest income was USD 1.27 million, compared with USD 0.66 million.
Operating Expenses
Research and development expenses were USD 4.44 million, compared with USD 2.59 million, and general and administrative expenses were USD 3.03 million, compared with USD 1.50 million. Total operating expenses were USD 7.47 million, compared with USD 4.09 million.
Weighted average basic and diluted shares outstanding were 8,561,371, compared with 7,123,849.
Nine-Month Results
For the nine months ended September 30, 2026, the net loss was USD 15.40 million, compared with USD 8.52 million, and the loss per share was USD 1.80, compared with USD 1.21. Research and Development expenses were USD 12.69 million, compared with USD 5.96 million, and general and administrative expenses were USD 6.65 million, compared with USD 4.59 million.
Total operating expenses for the nine months were USD 19.34 million, compared with USD 10.55 million, and interest income was USD 3.90 million, compared with USD 2.03 million.
Balance Sheet and Programs
Cash and cash equivalents were USD 52.63 million, compared with USD 61.83 million at December 31, 2025, and investments were USD 76.81 million, compared with USD 78.57 million. Total current Assets were USD 129.88 million, compared with USD 140.46 million, and total assets were USD 130.25 million, compared with USD 140.72 million.
Other current assets were USD 435 thousand, compared with USD 64 thousand. The filing reports that anti-dilutive potential common stock equivalents were excluded from the calculation of net loss per share.
The filing describes ALXN1840 as a late-stage, investigational once-daily, oral medicine for Wilson disease. It states that a completed pivotal Phase 3 trial met its primary endpoint, and that Alexion Pharmaceuticals, Inc., a Subsidiary of AstraZeneca, terminated the ALXN1840 program in Wilson disease based on a review of results from Phase 2 mechanistic trials and discussions with regulatory authorities. It states that, in the near term, the company is focused on assembling a regulatory package and completing the rolling submission of the new drug application for ALXN1840, with uncertain outcomes.
The company's radiopharmaceutical programs consist of MNPR-101-Zr (Phase 1) for imaging advanced cancers, and MNPR-101-Lu (Phase 1a) and MNPR-101-Ac (late preclinical) for the treatment of advanced cancers that express urokinase plasminogen activator receptor. The filing also states that pre-funded warrants are exercisable at a nominal price and are considered, in substance, equivalent to outstanding common stock.
Monopar Therapeutics Q3 2026 Earnings: Key Takeaways
Monopar Therapeutics reported a third quarter 2026 loss per share of USD 0.72 and a net loss of USD 6.20 million. Research and development expenses were USD 4.44 million, and total assets were USD 130.25 million.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...